Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
暂无分享,去创建一个
W. London | P. Thorner | R. Marcus | V. Joshi | K. Murray | M. Kletzel | R. Castleberry | C. Kretschmar | E. I. Smith | Cynthia S. Kretschmar | E. I. Smith | Wendy B. London | E. Smith
[1] W. Meyer,et al. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Bernstein,et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] K. Matthay,et al. Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. , 2000, Medical and Pediatric Oncology.
[4] D. Frappaz,et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Whitlock,et al. Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] K K Matthay,et al. Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .
[7] M. Harris,et al. #465 Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group (POG) phase II study , 1999 .
[8] P. Burger,et al. Topotecan for the Treatment of Recurrent or Progressive Central Nervous System Tumors – A Pediatric Oncology Group Phase II Study , 1999, Journal of Neuro-Oncology.
[9] M. Bernstein,et al. Topotecan in Pediatric Patients With Recurrent and Progressive Solid Tumors: A Pediatric Oncology Group Phase II Study , 1998, Journal of pediatric hematology/oncology.
[10] E. Eisenhauer,et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Uttenreuther-Fischer,et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] P. Houghton,et al. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. , 1998, Journal of the National Cancer Institute.
[13] D. Frappaz,et al. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Stewart,et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] P. Adamson,et al. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[16] K. Matthay. Neuroblastoma: biology and therapy. , 1997, Oncology.
[17] J. Verweij,et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] P. Houghton,et al. Schedule‐dependent Efficacy of Camptothecins in Models of Human Cancer a , 1996, Annals of the New York Academy of Sciences.
[19] J. Kurtzberg,et al. Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five‐Day Course in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study , 1996, Journal of pediatric hematology/oncology.
[20] S. Sallan,et al. Phase II evaluation of topotecan for pediatric central nervous system tumors , 1996 .
[21] K. Matthay,et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] A. Cantor,et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. , 1995, Medical and pediatric oncology.
[23] A. Cantor,et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] W. Furman,et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] F. Berthold,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.
[26] D N Shapiro,et al. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. , 1993, The American journal of pathology.
[27] E K Rowinsky,et al. The current status of camptothecin analogues as antitumor agents. , 1993, Journal of the National Cancer Institute.
[28] I. Ringel,et al. Direct photoaffinity labeling of tubulin with taxol. , 1992, Journal of the National Cancer Institute.
[29] G. Hortobagyi,et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. , 1991, Journal of the National Cancer Institute.
[30] D. Ettinger,et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. , 1989 .
[31] S. Sallan,et al. Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Rogers,et al. Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] H. Varmus,et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.
[34] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[35] J. Meza,et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] M. Tan,et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors , 1999, Cancer Chemotherapy and Pharmacology.
[37] G. Dini,et al. Unpurged ABMT for neuroblastoma: AIEOP-BMT experience. , 1991, Bone marrow transplantation.
[38] J. Shuster,et al. High-dose chemoradiotherapy supported by marrow infusions for advanced neuroblastoma: a Pediatric Oncology Group study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] D. Sarrazin,et al. [Neuroblastomas treated at the Gustave-Roussy Institute from 1975 to 1979. 173 cases]. , 1983, Archives francaises de pediatrie.